Welcome to our dedicated page for Vivani Medical news (Ticker: VANI), a resource for investors and traders seeking the latest updates and insights on Vivani Medical stock.
Vivani Medical, Inc. reports developments from a clinical-stage biopharmaceutical business focused on miniature, ultra long-acting subdermal drug implant candidates using its proprietary NanoPortal™ technology. News commonly centers on financial results, business updates, manufacturing and clinical-development spending, and progress for semaglutide-based implant candidates such as NPM-139 for chronic weight management and NPM-133 for type 2 diabetes.
The company’s updates also cover Cortigent, its wholly owned subsidiary developing brain implant devices based on precision neurostimulation technology. Cortigent disclosures include the Orion® Visual Cortical Prosthesis System, a cortical stimulation system under development to provide visual perception for blind persons, as well as equity financings, registered direct offerings, private placements, shareholder matters and governance updates.
Vivani Medical (NASDAQ: VANI) announced it will present at the Emerging Growth Conference on July 15, 2026. CEO Adam Mendelsohn, Ph.D., will provide a company update in an interactive session scheduled for 4:10 p.m. Eastern Time, with live Q&A and an archived webcast available afterward.
Vivani Medical (Nasdaq: VANI) signed a new agreement with Novo Nordisk to allow a non-exclusive internal evaluation of NPM-139, a semaglutide implant using Vivani’s NanoPortal™ technology for chronic weight management.
Vivani also expects to begin a Phase 1 first-in-human study of NPM-139 with Wegovy injections as an active comparator in mid-2026, focused on safety, pharmacokinetics, and tolerability to support a potential Phase 2 dose-ranging trial.
Vivani (Nasdaq: VANI) entered a definitive merger agreement under which its wholly owned subsidiary Cortigent will merge with a ClearOne (Nasdaq: CLRO) subsidiary and become a wholly owned ClearOne unit. Vivani will receive 12,500,000 ClearOne shares and is expected to own 59.4%–67.5% of the combined company.
ClearOne will be renamed Cortigent Holdings, trading on Nasdaq as CRGT. ClearOne plans a concurrent $10–$15 million registered financing. Closing is targeted for Q3 2026, subject to stockholder approvals, financing, minimum net cash, and continued Nasdaq listing.
ClearOne (Nasdaq: CLRO) entered a definitive merger agreement with Cortigent, a wholly-owned subsidiary of Vivani Medical (Nasdaq: VANI). Cortigent will become a wholly-owned subsidiary of ClearOne at closing.
ClearOne plans a concurrent registered financing targeting a minimum of $10 million and a maximum of $15 million to support the combined company.
Vivani Medical (NASDAQ: VANI) announced the appointment of August J. Moretti to its board of directors and the retirement of Dr. Dean Baker.
Moretti will chair the Audit Committee and join the Compensation Committee, while Baker steps down after leading key board committees and guiding the Nano Precision Medical–Second Sight Medical Products merger.
Vivani Medical (Nasdaq: VANI) received approval from Bellberry, a human research ethics committee in Australia, to initiate SLIM-1, a Phase 1 clinical trial of NPM-139, a semaglutide implant for obesity and chronic weight management.
The company targets trial initiation in mid-2026, leveraging prior Phase 1 experience with NPM-119, and is preparing a potential dose-ranging efficacy trial, SLIM-2, pending successful SLIM-1 results.
Vivani Medical (NASDAQ: VANI) announced that CEO Adam Mendelsohn, Ph.D., will present a company overview at the 2026 BIO International Convention in San Diego.
The presentation is scheduled for Wednesday, June 24, 2026, at 2:15 p.m. PT in Theater 3 at the San Diego Convention Center, with additional investor and partner meetings planned.
Vivani Medical (NASDAQ: VANI) announced that CEO Adam Mendelsohn will present a company overview at the Jefferies Global Healthcare Conference in New York on June 4, 2026, from 11:05 a.m. to 11:35 a.m. ET. A replay will be available for 90 days on Vivani’s investor website.
Vivani Medical (Nasdaq: VANI) reported Q1 2026 results and a pipeline update. The SLIM-1™ Phase 1 trial of semaglutide implant NPM-139 is expected to start mid-2026, with top-line data by year-end. Vivani held about $28 million in cash and commitments, projected to fund operations through the first half of 2027, and reported a Q1 2026 net loss of $6.8 million. The company is also evaluating paths to separate neuromodulation subsidiary Cortigent into an independent public company.
Vivani Medical (Nasdaq: VANI) reported Q4 and full-year 2025 results and a business update highlighting clinical and preclinical progress for a semaglutide implant (NPM-139) and financing that extends runway into mid-2027.
The company reported sustained preclinical semaglutide exposure with >20% sham-adjusted weight loss for one year, plans to start a Phase 1 study mid-2026 with data possible by end-2026, and raised $41.5M in recent financings.